摘要
目的探究“调肝补肾法”中药制剂对乳腺癌细胞的作用及其机制。方法采用网络药理学方法预测“调肝补肾法”中药制剂的作用机制;CCK8法、单细胞克隆和划痕实验分别检测“调肝补肾法”中药制剂对人乳腺癌细胞MCF-7、T47D增殖活力、克隆形成和迁移能力的影响;蛋白质印迹法检测“调肝补肾法”中药制剂对磷酸化磷脂酰肌醇3激酶(PI3K)、Akt激酶的表达。结果网络药理学筛选出“活性成分-乳腺癌”靶点84个,作用机制与PI3K/Akt、促分裂原活化的蛋白质激酶等信号通路有关。细胞实验表明该“调肝补肾法”可抑制MCF7和T47D细胞的增殖、迁移能力,并降低p-PI3K、p-Akt蛋白表达水平。结论采用“调肝补肾法”中药制剂治疗乳腺癌,可能通过调控PI3K/Akt信号通路抑制人乳腺癌MCF-7和T47D细胞增殖、侵袭迁移。
Objective To explore the inhibitory effects of the Chinese medicinal therapy of"regulating the liver and tonifying the kidney"on breast cancer and to preliminarily study its mechanisms.Methods The network pharmacology method was used to predict the mechanisms of the therapy in"regulating the liver and tonifying the kidney";the Cell Counting Kit-8,single-cell cloning and scratch assays were used to detect the effects of the Chinese medicines on the proliferation,clone formation,and migration abilities of human breast cancer cells MCF-7 and T47D-Western blotting was used to detect the expression of phosphorylated phosphoinositide 3-kinase(PI3K)and Akt kinase proteins in the Chinese medicines.Results Network harmacology screened out 84 co-targets of "active components-breast cancer", and the mechanisms were related to signalingpathways such as PI3K/Akt and mitogen-activated protein kinase. In vitro experiments showed that theChinese medicines could inhibit the proliferation and migration of MCF7 and T47D cells, andreduce the expression levels of PI3K and Akt kinase proteins. Conclusion The "regulating the liver and tonifyingthe kidney" therapy can be used to treat breast cancer, may inhibit the proliferation and invasion of humanbreast cancer MCF-7 and T47D cells by regulating the PI3K/Akt signaling pathway.
作者
陆家凤
李朝燕
杨铭
马诗瑜
徐斌
李亚芬
王洁
杨晨
张惟郁
Lu Jiafeng;Li Chaoyan;Yang Ming;Ma Shiyu;Xu Bin;Li Yafen;Wang Jie;Yang Chen;Zhang Weiyu(Department of Pharmacy,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Department of Traditional Chinese Medicine,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Department of Breast Surgery,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Department of Oncology,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Department of Pharmacy,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)
出处
《兰州大学学报（医学版）》
2024年第7期12-21,共10页
Journal of Lanzhou University（Medical Sciences）
基金
上海市卫生和计划生育委员会中医药科研专项资助项目(2016LP017)
上海交通大学“交大之星”计划医工交叉研究基金资助项目(YG2019ZDB06)
上海交通大学医学院附属瑞金医院北院研究基金资助项目(2018ZY30)
上海交通大学医学院附属瑞金医院“青年基金培育计划”资助项目(KY20240295)
上海市嘉定区卫生健康委员会中医药科研课题资助项目(2023-KY-ZYY-02)。
关键词
乳腺癌
网络药理学
调肝补肾
增殖抑制
磷脂酰肌醇3激酶/Akt信号通路
breast cancer
network pharmacology
regulating the liver and tonifying the kidney
proliferation inhibition
phosphoinositide 3-kinase/Akt signaling pathway
